These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29262795)

  • 1. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial).
    Boerlage TCC; Haal S; Maurits de Brauw L; Acherman YIZ; Bruin S; van de Laar AWJM; Moes DE; van Wagensveld BA; de Vries CEE; van Veen R; Schouten R; Dijkgraaf MG; Fockens P; Gerdes VEA; Voermans RP
    BMC Gastroenterol; 2017 Dec; 17(1):164. PubMed ID: 29262795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial.
    Haal S; Guman MSS; Boerlage TCC; Acherman YIZ; de Brauw LM; Bruin S; de Castro SMM; van Hooft JE; van de Laar AWJM; Moes DE; Schouten M; Schouten R; van Soest EJ; van Veen RN; de Vries CEE; Fockens P; Dijkgraaf MGW; Gerdes VEA; Voermans RP
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):993-1001. PubMed ID: 34715031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: statistical analysis plan for a randomised controlled trial (UPGRADE trial).
    Haal S; Guman MSS; de Brauw LM; van Veen RN; Schouten R; Fockens P; Gerdes VEA; Dijkgraaf MGW; Voermans RP
    Trials; 2020 Jul; 21(1):676. PubMed ID: 32703246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of ursodeoxycholic acid in preventing new-onset symptomatic gallstone disease after Roux-en-Y gastric bypass surgery.
    Haal S; Guman MSS; de Brauw LM; Schouten R; van Veen RN; Fockens P; Gerdes VEA; Voermans RP; Dijkgraaf MGW
    Br J Surg; 2022 Oct; 109(11):1116-1123. PubMed ID: 35979609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Ursodeoxycholic Acid in the Prevention of Cholelithiasis After Sleeve Gastrectomy.
    Coupaye M; Calabrese D; Sami O; Siauve N; Ledoux S
    Obes Surg; 2019 Aug; 29(8):2464-2469. PubMed ID: 30945151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Ursodeoxycholic Acid for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer: The PEGASUS-D Randomized Clinical Trial.
    Lee SH; Jang DK; Yoo MW; Hwang SH; Ryu SY; Kwon OK; Hur H; Man Yoon H; Eom BW; Ahn HS; Son T; Song KY; Lee HH; Choi MG; An JY; Lee SI; Lee KH; Ahn S; Park YS; Park DJ;
    JAMA Surg; 2020 Aug; 155(8):703-711. PubMed ID: 32584935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1.
    Machado FHF; Castro Filho HF; Babadopulos RFAL; Rocha HAL; Rocha JLC; Moraes Filho MO
    Acta Cir Bras; 2019 Feb; 34(1):e20190010000009. PubMed ID: 30785510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Prospective Comparison of Ursodeoxycholic Acid for the Prevention of Gallstones after Sleeve Gastrectomy.
    Adams LB; Chang C; Pope J; Kim Y; Liu P; Yates A
    Obes Surg; 2016 May; 26(5):990-4. PubMed ID: 26342481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial.
    Miller K; Hell E; Lang B; Lengauer E
    Ann Surg; 2003 Nov; 238(5):697-702. PubMed ID: 14578732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with adherence to ursodeoxycholic acid or placebo in patients after bariatric surgery.
    Guman MSS; Haal S; Maurits de Brauw L; Hutten BA; Nieuwdorp PM; Nuijen B; Schouten R; van Veen RN; Dijkgraaf PMGW; Voermans RP; Gerdes VEA
    Surg Obes Relat Dis; 2022 Jun; 18(6):755-761. PubMed ID: 35387759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of Ursolit for gallstone prophylaxis following bariatric surgery: a randomized-controlled trial.
    Sakran N; Dar R; Assalia A; Neeman Z; Farraj M; Sherf-Dagan S; Gralnek IM; Hazzan R; Mokary SE; Nevo-Aboody H; Dola T; Kaplan U; Hershko D
    Updates Surg; 2020 Dec; 72(4):1125-1133. PubMed ID: 32666477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Incidence of Symptomatic Cholelithiasis After Bariatric Roux-En-Y Gastric Bypass and Previous Bariatric Surgery: a Single Center Experience.
    Sneineh MA; Harel L; Elnasasra A; Razin H; Rotmensh A; Moscovici S; Kais H; Shirin H
    Obes Surg; 2020 Mar; 30(3):846-850. PubMed ID: 31901127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic Acid for 6 Months After Bariatric Surgery Is Impacting Gallstone Associated Morbidity in Patients with Preoperative Asymptomatic Gallstones.
    Della Penna A; Lange J; Hilbert J; Archid R; Königsrainer A; Quante M
    Obes Surg; 2019 Apr; 29(4):1216-1221. PubMed ID: 30604076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid for prevention of gallstone disease after laparoscopic sleeve gastrectomy: an Atlantic Canada perspective.
    Hossain I; Brodie J; O'Brien E; Tedman-Aucoin K; Lawlor D; Murphy R; Twells L; Pace D; Evans B; Ellsmere J
    Surg Endosc; 2023 Jul; 37(7):5236-5240. PubMed ID: 36952047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors for Symptomatic Gallstone Disease and Gallstone Formation After Bariatric Surgery.
    Haal S; Guman MSS; Bruin S; Schouten R; van Veen RN; Fockens P; Dijkgraaf MGW; Hutten BA; Gerdes VEA; Voermans RP
    Obes Surg; 2022 Apr; 32(4):1270-1278. PubMed ID: 35143012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Ursodeoxycholic Acid (UDCA) in Cholelithiasis Management After One Anastomosis Gastric Bypass (OAGB) for Morbid Obesity: Results of a Monocentric Randomized Controlled Trial.
    Pizza F; D'Antonio D; Lucido FS; Tolone S; Del Genio G; Dell'Isola C; Docimo L; Gambardella C
    Obes Surg; 2020 Nov; 30(11):4315-4324. PubMed ID: 32583297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: a meta-analysis.
    Uy MC; Talingdan-Te MC; Espinosa WZ; Daez ML; Ong JP
    Obes Surg; 2008 Dec; 18(12):1532-8. PubMed ID: 18574646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients developed symptomatic gallstones between 3 and 21 months after Roux-en-Y gastric bypass (RYGB), neither prophylactic cholecystectomy nor treatment with ursodeoxycholic acid is necessary after open RYGB.
    Sarr MG
    Surg Obes Relat Dis; 2006; 2(2):233; author reply 233. PubMed ID: 16925352
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of biliary complications in bariatric surgery.
    Desbeaux A; Hec F; Andrieux S; Fayard A; Bresson R; Pruvot MH; Mulliez E
    J Visc Surg; 2010 Aug; 147(4):e217-20. PubMed ID: 20920904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of incidence of cholelithiasis after bariatric surgery in subjects treated or not treated with ursodeoxycholic acid.
    Coupaye M; Calabrese D; Sami O; Msika S; Ledoux S
    Surg Obes Relat Dis; 2017 Apr; 13(4):681-685. PubMed ID: 28089591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.